Oxygen gradient ektacytometry-derived biomarkers are associated with acute complications in sickle cell disease.

"Conflict-of-interest disclosure: C.B. and J.B. received grant funding from RR Mechatronics. M.A.E.R. and R.v.W. received grant funding from 10.13039/100016471Agios Pharmaceuticals, 10.13039/100020807Axcella Health, and RR Mechatronics. R.v.W. received grant funding from 10.13039/100016471Agios Pharmaceuticals, Global Blood Therapeutics, 10.13039/100020807Axcella Health, and RR Mechatronics. P.C. received grant funding from 10.13039/100016471Agios Pharmaceuticals and RR Mechatronics. M.H.C. received grant funding from 10.13039/100007723Takeda, Shire, 10.13039/100004702Baxter, 10.13039/100004326Bayer, 10.13039/501100012112Sobi, 10.13039/100008322CSL Behring, 10.13039/501100014812Nordic Pharma, 10.13039/501100004191Novo Nordisk, and 10.13039/100004319Pfizer; (institution) has received investigator-initiated research and travel grants as well as speaker fees over the years from The Netherlands Organisation for Scientific Research and Netherlands National research Agenda, The Netherlands Organization for Health Research and Development (ZonMw), the Dutch Innovatiefonds Zorgverzekeraars, Baxter/Baxalta/Shire/Takeda, Pfizer, Bayer Schering Pharma, CSL Behring, Sobi Biogen, Novo Nordisk, Novartis, and Nordic Pharma; and has served as a steering board member for Roche, Bayer, and Novartis for which fees go to the Erasmus MC as an institution. V.A.S. received grant funding from National Heart, Lung, and Blood Institute Cure SCD Initiative, Global Blood Therapeutics, Beam Therapeutics, Emmaus, and 10.13039/100004336Novartis for investigator-initiated research projects. E.J.v.B. received grant funding 10.13039/100016471Agios Pharmaceuticals, RR Mechatronics, 10.13039/100004336Novartis, and 10.13039/100004319Pfizer for investigator-initiated research projects. The remaining authors have declared no competing financial interests."

"M.A.E.R., M.E.H., A.W.R., E.N., M.H.C. and E.J.v.B. are clinical researchers within the Sickle Cell Outcome Research consortium, a multicenter clinical research collaboration in The Netherlands, which gave input on the work described in this manuscript, which the authors value highly. This work has been funded in part by 10.13039/100013297Eurostars grant estar18105 and by an unrestricted grant provided by RR Mechatronics. This work is also funded in part by a K08 grant from the 10.13039/100000062National Institute of Diabetes and Digestive and Kidney Diseases and provided with support from the 10.13039/100018130Department of Pediatrics, Baylor College of Medicine."